# Yonsei whole-genome cell-free DNA multi-cancer platform study

Source: https://onco.cc/trials/yonsei-mced-wgs/  
OnCo record `yonsei-mced-wgs` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A South Korean study building a multi-cancer blood test from whole-genome sequencing of circulating DNA.

## Summary

Yonsei whole-genome cell-free DNA multi-cancer platform study (NCT06231953) is an observational study sponsored by Yonsei University. It aims to establish a multi-cancer early detection platform through whole-genome sequencing of circulating DNA.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 4,000 participants, a start on 13 October 2022 and primary completion expected in December 2026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Registry id: NCT06231953
- Phase: observational
- Setting: People with invasive cancer and healthy volunteers at up to 10 South Korean institutions
- Sponsor: Yonsei University
- Enrolled: 4000

## Sources

- ClinicalTrials.gov NCT06231953: https://clinicaltrials.gov/study/NCT06231953

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- trials: [Yonsei whole-genome cell-free DNA multi-cancer platform: development, validation and confirmation](https://onco.cc/trials/yonsei-mced-wgs-2/)

---
JSON: https://onco.cc/api/v1/entities/yonsei-mced-wgs.json